Scinovex
articleTop 1% cited

High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients

Nephrology Dialysis Transplantation · 2009 · Vol. 24(9) · pp. 2792–2796
Guillaume JeanJ.-C. TerratThierry VanelJ.M. HurotChristie LorriauxBrice MayorC. Chazot

Abstract

This study demonstrated a high level of circulating FGF-23 in LHD patients, despite infrequent hyperphosphataemia. However, phosphataemia is still the main factor correlating with serum FGF-23. The association of higher serum FGF-23 levels with mortality and VC, regardless of the serum phosphate levels, has thus been confirmed.

Parathyroid Disorders and TreatmentsPancreatitis Pathology and TreatmentDialysis and Renal Disease ManagementMedicineFibroblast growth factor 23Fibroblast growth factorHemodialysisInternal medicineFibroblastEndocrinologyFGF21BiochemistryIn vitro

MeSH terms

Fibroblast Growth Factor-23AgedAged, 80 and overFemaleFibroblast Growth FactorsFranceRenal DialysisHumansKidney Failure, ChronicMaleMiddle AgedProspective StudiesRisk FactorsTime FactorsMultivariate Analysis
Citations
346
FWCI
17.81
field-weighted impact
References
24
Percentile
100%
vs. same field & year
Citations per year
Cited by
FGF23 induces left ventricular hypertrophy
Journal of Clinical Investigation · 2011 · 1,972 citations
References
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients · Scinovex